While I do agree with you about BIT225 being a good candidate as the next gen anti-viral - and I hope this will be an avenue that BIT engages in. The situation is that the trials have not been don on this application.
Information can b gleaned from the two trials BUT there would need to be a separate set of trials to test the anti-viral potential.
This is why trials are done in the first place.
$10 Billion Deal, page-13026
-
- There are more pages in this discussion • 242 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
